用于癌症治疗的多靶点多聚芳香醚疗法。理论概念和建议。

IF 2.9 3区 医学 Q2 ONCOLOGY Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-08 DOI:10.1080/14737140.2024.2372336
Alfonso Duenas-Gonzalez, Aurora Gonzalez-Fierro, Leticia Bornstein-Quevedo, Francisco Gutierrez-Delgado, Richard E Kast, Alma Chavez-Blanco, Guadalupe Dominguez-Gomez, Myrna Candelaria, Adriana Romo-Pérez, Jose Correa-Basurto, Marcela Lizano, Veronica Perez-de la Cruz, Benjamin Robles-Bañuelos, David Nuñez-Corona, Erandi Martinez-Perez, Emma Verastegui
{"title":"用于癌症治疗的多靶点多聚芳香醚疗法。理论概念和建议。","authors":"Alfonso Duenas-Gonzalez, Aurora Gonzalez-Fierro, Leticia Bornstein-Quevedo, Francisco Gutierrez-Delgado, Richard E Kast, Alma Chavez-Blanco, Guadalupe Dominguez-Gomez, Myrna Candelaria, Adriana Romo-Pérez, Jose Correa-Basurto, Marcela Lizano, Veronica Perez-de la Cruz, Benjamin Robles-Bañuelos, David Nuñez-Corona, Erandi Martinez-Perez, Emma Verastegui","doi":"10.1080/14737140.2024.2372336","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The pharmacological treatment of cancer has evolved from cytotoxic to molecular targeted therapy. The median survival gains of 124 drugs approved by the FDA from 2003 to 2021 is 2.8 months. Targeted therapy is based on the somatic mutation theory, which has some paradoxes and limitations. While efforts of targeted therapy must continue, we must study newer approaches that could advance therapy and affordability for patients.</p><p><strong>Areas covered: </strong>This work briefly overviews how cancer therapy has evolved from cytotoxic chemotherapy to current molecular-targeted therapy. The limitations of the one-target, one-drug approach considering cancer as a robust system and the basis for multitargeting approach with polypharmacotherapy using repurposing drugs.</p><p><strong>Expert opinion: </strong>Multitargeted polypharmacotherapy for cancer with repurposed drugs should be systematically investigated in preclinical and clinical studies. Remarkably, most of these proposed drugs already have a long history in the clinical setting, and their safety is known. In principle, the risk of their simultaneous administration should not be greater than that of a first-in-human phase I study as long as the protocol is developed with strict vigilance to detect early possible side effects from their potential interactions. Research on cancer therapy should go beyond the prevailing paradigm targeted therapy.</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Multitargeted polypharmacotherapy for cancer treatment. theoretical concepts and proposals.\",\"authors\":\"Alfonso Duenas-Gonzalez, Aurora Gonzalez-Fierro, Leticia Bornstein-Quevedo, Francisco Gutierrez-Delgado, Richard E Kast, Alma Chavez-Blanco, Guadalupe Dominguez-Gomez, Myrna Candelaria, Adriana Romo-Pérez, Jose Correa-Basurto, Marcela Lizano, Veronica Perez-de la Cruz, Benjamin Robles-Bañuelos, David Nuñez-Corona, Erandi Martinez-Perez, Emma Verastegui\",\"doi\":\"10.1080/14737140.2024.2372336\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The pharmacological treatment of cancer has evolved from cytotoxic to molecular targeted therapy. The median survival gains of 124 drugs approved by the FDA from 2003 to 2021 is 2.8 months. Targeted therapy is based on the somatic mutation theory, which has some paradoxes and limitations. While efforts of targeted therapy must continue, we must study newer approaches that could advance therapy and affordability for patients.</p><p><strong>Areas covered: </strong>This work briefly overviews how cancer therapy has evolved from cytotoxic chemotherapy to current molecular-targeted therapy. The limitations of the one-target, one-drug approach considering cancer as a robust system and the basis for multitargeting approach with polypharmacotherapy using repurposing drugs.</p><p><strong>Expert opinion: </strong>Multitargeted polypharmacotherapy for cancer with repurposed drugs should be systematically investigated in preclinical and clinical studies. Remarkably, most of these proposed drugs already have a long history in the clinical setting, and their safety is known. In principle, the risk of their simultaneous administration should not be greater than that of a first-in-human phase I study as long as the protocol is developed with strict vigilance to detect early possible side effects from their potential interactions. Research on cancer therapy should go beyond the prevailing paradigm targeted therapy.</p>\",\"PeriodicalId\":12099,\"journal\":{\"name\":\"Expert Review of Anticancer Therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Anticancer Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737140.2024.2372336\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2024.2372336","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言: .癌症的药物治疗已从细胞毒性治疗发展到分子靶向治疗。从 2003 年到 2021 年,美国食品和药物管理局批准的 124 种药物的中位生存期为 2.8 个月。靶向治疗以体细胞突变理论为基础,存在一些悖论和局限性。在继续开展靶向治疗的同时,我们必须研究更新的方法,以提高治疗效果和患者的经济承受能力:本著作简要概述了癌症治疗如何从细胞毒性化疗发展到目前的分子靶向治疗。考虑到癌症是一个稳健的系统,单靶点、单药物疗法存在局限性,而多靶点多药物疗法则是利用药物再利用的基础:专家意见:应在临床前和临床研究中系统地研究使用重新确定用途的药物对癌症进行多靶点多药治疗的方法。值得注意的是,这些拟议药物中的大多数已经在临床上应用了很长时间,其安全性也已众所周知。原则上,只要在制定方案时严格把关,及早发现这些药物之间可能发生的相互作用而可能产生的副作用,那么同时使用这些药物的风险应该不会大于首次人体 I 期研究的风险。癌症治疗研究应超越目前流行的靶向治疗模式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Multitargeted polypharmacotherapy for cancer treatment. theoretical concepts and proposals.

Introduction: The pharmacological treatment of cancer has evolved from cytotoxic to molecular targeted therapy. The median survival gains of 124 drugs approved by the FDA from 2003 to 2021 is 2.8 months. Targeted therapy is based on the somatic mutation theory, which has some paradoxes and limitations. While efforts of targeted therapy must continue, we must study newer approaches that could advance therapy and affordability for patients.

Areas covered: This work briefly overviews how cancer therapy has evolved from cytotoxic chemotherapy to current molecular-targeted therapy. The limitations of the one-target, one-drug approach considering cancer as a robust system and the basis for multitargeting approach with polypharmacotherapy using repurposing drugs.

Expert opinion: Multitargeted polypharmacotherapy for cancer with repurposed drugs should be systematically investigated in preclinical and clinical studies. Remarkably, most of these proposed drugs already have a long history in the clinical setting, and their safety is known. In principle, the risk of their simultaneous administration should not be greater than that of a first-in-human phase I study as long as the protocol is developed with strict vigilance to detect early possible side effects from their potential interactions. Research on cancer therapy should go beyond the prevailing paradigm targeted therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.10
自引率
3.00%
发文量
100
审稿时长
4-8 weeks
期刊介绍: Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.
期刊最新文献
Statin use and ovarian cancer Outcomes. Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters. Impact of the 21-gene recurrence score testing on chemotherapy selection and clinical outcomes in T3N0 luminal breast cancer. The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer. Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1